Andrei Gudkov and Mikhail Blagoskionny, two of the nation’s leading oncological physicians and the editors of Oncotarget, have recently discussed the new science emerging regarding the anti-aging industry. Although the industry has become largely profitable because of the mass production of merchandise designed to sway gullible consumers, Oncotarget has released research that shows scientists are making progress toward the age old goal of invincibility. In Oncotarget’s most recently published article on the subject, Matt Kaeberlin relays the most recent developments in the study of aging science. Oncotarget editors have stated that the research submitted in this article is extremely beneficial to the medical community at large. Check the journal at SCImago Journal & Country Rank.
As the head of the Department of Aging Science at the University of Washington, Dr. Kaeberlin has been a witness to the many highs and lows associated with the study of human aging. The early days of aging science found most scientists convinced that aging was ultimately caused by the body’s reaction to its surroundings. After all, they deduced, nature could not produce a human body that was completely functional only to have it deteriorate over time. Although a large portion of modern scientists still have not admitted that nature, which was itself created, does not have to power to create a human body, they have evolved in their reasoning enough to conclude that the body’s deterioration is not caused by the environment but by factors within the human genome. According to the recent Oncotarget article on the subject, genetic factors may be completely responsible for the human aging process.
Effect on Anti-Aging Market
What does this research mean for the multi-billion dollar anti-aging market? Dr. Kaeberlin reported that the scientific findings that link human genes to the aging process can be quite detrimental to manufacturers hoping to cash in on research efforts. Oncotarget is expected to publish additional anti-aging research in the near future. Follow Oncotarget journal on Twitter.